SEC Form 13F
| Report period | 2026-06-30 |
|---|---|
| Publicly available | 2026-08-15 |
| Reported value | $2,201,787,906 |
| Positions | 41 |
| Issuer | Ticker | Class | Reported value | Reported amount |
|---|---|---|---|---|
| AURINIA PHARMACEUTICALS INC | AUPH | COM | $221,358,479 | 13,044,106 |
| SPYRE THERAPEUTICS INC | SYRE | COM NEW | $167,989,516 | 1,892,200 |
| MIRUM PHARMACEUTICALS INC | MIRM | COM | $144,701,681 | 1,236,027 |
| KINIKSA PHARMACEUTICALS INTL | KNSA | ORD SHS CL A | $144,519,902 | 2,259,889 |
| CELCUITY INC | CELC | COM | $137,532,824 | 1,314,594 |
| CORCEPT THERAPEUTICS INC | CORT | COM | $130,425,000 | 1,500,000 |
| PTC THERAPEUTICS INC | PTCT | COM | $122,355,000 | 1,500,000 |
| LAKEFRONT BIOTHERAPEUTICS NV | LKFT | SPON ADR | $113,504,010 | 3,785,991 |
| CAPRICOR THERAPEUTICS INC | CAPR | COM NEW | $98,725,592 | 4,099,900 |
| TARSUS PHARMACEUTICALS INC | TARS | COM | $98,706,662 | 1,568,266 |
Public filing evidence only. NexusTrade's simulated follower strategies are hypothetical, modeled results — not live trading returns and not investment advice.